Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC By Ogkologos - May 19, 2026 80 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PLANeT study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 The Largest Randomised Study to Date Points to Low Ipsilateral Breast... June 22, 2023 A call to action: how our Campaigns Ambassadors are shaping the... May 6, 2022 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... May 10, 2021 Load more HOT NEWS March is Multiple Myeloma Action Month Study Adds to Debate about Screening for Melanoma ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration... FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene...
